Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) COO James B. Weissman Sells 20,000 Shares

Share on StockTwits

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) COO James B. Weissman sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $26.00, for a total transaction of $520,000.00. Following the transaction, the chief operating officer now owns 34,704 shares of the company’s stock, valued at approximately $902,304. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Dicerna Pharmaceuticals stock opened at $25.89 on Wednesday. The stock has a 50 day moving average of $19.15 and a two-hundred day moving average of $15.37. Dicerna Pharmaceuticals Inc has a twelve month low of $9.31 and a twelve month high of $26.69. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -21.57 and a beta of 2.38.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.15). Dicerna Pharmaceuticals had a negative net margin of 541.24% and a negative return on equity of 58.92%. The company had revenue of $8.04 million during the quarter, compared to analyst estimates of $11.70 million. As a group, equities analysts predict that Dicerna Pharmaceuticals Inc will post -1.28 EPS for the current year.

A number of equities research analysts have commented on DRNA shares. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. BidaskClub upgraded Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 9th. ValuEngine downgraded Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target (up from $22.00) on shares of Dicerna Pharmaceuticals in a report on Tuesday, November 19th. Finally, Robert W. Baird boosted their price objective on shares of Dicerna Pharmaceuticals from $35.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $27.38.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Dicerna Pharmaceuticals by 52.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,363 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 1,151 shares during the last quarter. Quantamental Technologies LLC boosted its stake in shares of Dicerna Pharmaceuticals by 94.4% in the second quarter. Quantamental Technologies LLC now owns 3,500 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 1,700 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of Dicerna Pharmaceuticals in the second quarter valued at approximately $68,000. Athanor Capital LP acquired a new position in Dicerna Pharmaceuticals during the second quarter worth $233,000. Finally, Metropolitan Life Insurance Co NY grew its holdings in Dicerna Pharmaceuticals by 5.1% during the third quarter. Metropolitan Life Insurance Co NY now owns 18,110 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 879 shares during the period. 84.77% of the stock is currently owned by institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Read More: The Role of a Fiduciary and Individual Investors

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.